In the weed world, Big Pharma is typically seen as an enemy. It’s the industry that pushed opioids over a potentially safer solution to chronic pain. It’s the industry that has scored Schedule II and III status for synthetic THC, while naturally occurring THC in cannabis plants remain in Schedule I. It’s the industry that has poured money into lobbying against marijuana legalization efforts, while simultaneously selling the aforementioned synthetic THC.
But New York medical marijuana company PharmaCannis is taking techniques from pharmaceutical drug development and applying them to the plant. It’s using something known as the self-emulsifying drug delivery system to produce their PharmaCannis Capsules, increasing the efficacy of its plant-derived medical marijuana products. Well-known in the biotech world, the company says it’s the first